Presented at 2023 SITC Meeting
- A pre-planned biomarker analysis of patients treated with bemcentinib in
combination with KEYTRUDA® (pembrolizumab) yields new understandings-
BERGEN, Norway, November 6, 2023 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, announced that a poster presentation detailing
additional data from a Phase II trial of bemcentinib in combination with MSD's
anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in second line Non-Small Cell Lung
Cancer (NSCLC) patients was presented on November 4th at the 2023 Society of
Immunotherapy of Cancer Annual Meeting.
The pre-planned biomarker analysis of the BGBC008 study in 2L NSCLC patients
adds to the clinical data recently announced at the 2023 ESMO meeting. The
poster presentation entitled "Bemcentinib + Pembrolizumab show promising
efficacy in metastatic NSCLC patients harboring mutations associated with poor
prognosis: exploratory sub-analysis from the BGBC008 Trial", is now available on
BerGenBio's website under the Scientific Publications section.
Martin Olin, Chief Executive Officer of BerGenBio, commented "The findings add
to the industry's understanding of the outcomes in 2L NSCLC patients and the
potential for bemcentinib to benefit patients in combination with immune
checkpoint inhibition. While the dataset in the analyses is relatively small, we
believe bemcentinib in combination with pembrolizumab has the potential to
improve outcomes in NSCLC patient sub-groups that have been associated with poor
survival, including patients with negative/low PD-L1 levels, STK11 mutations,
and KEAP1 mutations".
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of
Merck & Co., Inc., Rahway, NJ, USA
-End-
Contacts
Martin Olin CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
Investor Relations / Media Relations
Jan Lilleby
jl@lillebyfrisch.no
About Bemcentinib
Bemcentinib is a potentially first-in-class, potent and highly selective
inhibitor of the tyrosine kinase AXL. Extensive studies confirm the ability to
combine bemcentinib with immune checkpoint inhibitors, chemotherapies and
targeted therapies with the goal of improving a patient's immune response and
delaying the development of chemoresistance. Bemcentinib is currently being
investigated in combination with immune checkpoint inhibition and chemotherapy
in first line NSCLC patients harboring mutations in the STK11 gene, a known
prognostic factor of poor response to existing therapies.
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and COVID-19.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visitwww.bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.